Cancer Immunotherapy Guidelines Lymphoma Subcommittee

The disease-specific Cancer Immunotherapy Guidelines Subcommittees monitor the advancements in the cancer immunotherapy treatment options as indicated by FDA approvals of agents and companion diagnostic tools to publish and update evidence-based manuscripts for the clinical care team to utilize as a set of guidelines for treatment indications in those specific disease area. These guidelines provide key indicators to help determine when the use of immunotherapy is appropriate for cancer patient treatment. 

Current Members
4 Members